Theranostic Imaging of Yttrium-90

Wright, Chadwick; Zhang, Jun; Tweedle, Michael F.; Knopp, Michael V.; Hall, Nathan C.

doi:10.1155/2015/481279

Cited by 61 publications

(52 citation statements)

References 86 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The production of 55 Co via the 54 Fe(d,n) 55 Co reaction using electroplated enriched iron targets has also been reported. In a recent example of this work, a branched DGA resin was employed for the purification and resulted in a high purity product in a small volume.…”

Section: Comentioning

confidence: 97%

“…PET and optical imaging as novel imaging approaches for noninvasively detecting 90 Y radioactivity in vitro and in vivo present new opportunities for future development of theranostic agents. The utilization of 90 Y‐targeted radiotherapies is anticipated to increase in future …”

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

“…While less studied than some of the other radiometals discussed, 55 Co (T 1/2 = 17.5 h) offers slightly different chemistry and the potential for better in vivo stability than some of the radiocopper analogues. 130,131 55 Co has also been used for imaging in the form of a simple metal salt to study various disease processes.…”

Section: Comentioning

confidence: 99%

“…130,131 55 Co has also been used for imaging in the form of a simple metal salt to study various disease processes. [132][133][134] The production and purification of 55 Co is typically via the 58 Ni(p,α) 55 Co reaction and follows similar chemistry to the production of 64 Cu. 135,136 Natural Ni target foils or targets prepared with enriched 58 Ni electroplated on copper, gold, or silver backings are irradiated with proton energies of 10 to 15 MeV.…”

Section: Comentioning

confidence: 99%

“…135,136 Natural Ni target foils or targets prepared with enriched 58 Ni electroplated on copper, gold, or silver backings are irradiated with proton energies of 10 to 15 MeV. 130,135,137 While the cross section for 55 Co is higher at higher energies, 138 typically the irradiation of targets is carried out at lower proton energies to minimize the production of 57 Co, which is produced either directly by the 60 Ni(p,α) 57 Co reaction when using Ni targets of natural composition or from the decay of 57 Ni that is produced via the 58 Ni(p,pn) 57 Ni reaction. The purification procedures for 55 Co produced using Ni targets are typically similar to those employed for 64 Cu.…”

Section: Comentioning

confidence: 99%

See 4 more Smart Citations

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.

show abstract

Section: Comentioning

confidence: 97%

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

Section: Comentioning

confidence: 99%

Section: Comentioning

confidence: 99%

Section: Comentioning

confidence: 99%

See 3 more Smart Citations

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

Engineered Antibodies as Cancer Radiotheranostics

Wei,

Li,

Wen

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Radiotheranostics is a rapidly growing approach in personalized medicine, merging diagnostic imaging and targeted radiotherapy to allow for the precise detection and treatment of diseases, notably cancer. Radiolabeled antibodies have become indispensable tools in the field of cancer theranostics due to their high specificity and affinity for cancer‐associated antigens, which allows for accurate targeting with minimal impact on surrounding healthy tissues, enhancing therapeutic efficacy while reducing side effects, immune‐modulating ability, and versatility and flexibility in engineering and conjugation. However, there are inherent limitations in using antibodies as a platform for radiopharmaceuticals due to their natural activities within the immune system, large size preventing effective tumor penetration, and relatively long half‐life with concerns for prolonged radioactivity exposure. Antibody engineering can solve these challenges while preserving the many advantages of the immunoglobulin framework. In this review, the goal is to give a general overview of antibody engineering and design for tumor radiotheranostics. Particularly, the four ways that antibody engineering is applied to enhance radioimmunoconjugates: pharmacokinetics optimization, site‐specific bioconjugation, modulation of Fc interactions, and bispecific construct creation are discussed. The radionuclide choices for designed antibody radionuclide conjugates and conjugation techniques and future directions for antibody radionuclide conjugate innovation and advancement are also discussed.

show abstract

Aligning physics and physiology: Engineering antibodies for radionuclide delivery

Tsai

2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The exquisite specificity of antibodies and antibody fragments renders them excellent agents for targeted delivery of radionuclides. Radiolabeled antibodies and fragments have been successfully used for molecular imaging and radioimmunotherapy (RIT) of cell surface targets in oncology and immunology. Protein engineering has been used for antibody humanization essential for clinical applications, as well as optimization of important characteristics including pharmacokinetics, biodistribution, and clearance. Although intact antibodies have high potential as imaging and therapeutic agents, challenges include long circulation time in blood, which leads to later imaging time points post-injection and higher blood absorbed dose that may be disadvantageous for RIT. Using engineered fragments may address these challenges, as size reduction and removal of Fc function decreases serum half-life. Radiolabeled fragments and pretargeting strategies can result in high contrast images within hours to days, and a reduction of RIT toxicity in normal tissues. Additionally, fragments can be engineered to direct hepatic or renal clearance, which may be chosen based on the application and disease setting. This review discusses aligning the physical properties of radionuclides (positron, gamma, beta, alpha, and Auger emitters) with antibodies and fragments and highlights recent advances of engineered antibodies and fragments in preclinical and clinical development for imaging and therapy.

show abstract

Theranostic Imaging of Yttrium-90

Cited by 61 publications

References 86 publications

Radiometals for imaging and theranostics, current production, and future perspectives

Radiometals for imaging and theranostics, current production, and future perspectives

Engineered Antibodies as Cancer Radiotheranostics

Aligning physics and physiology: Engineering antibodies for radionuclide delivery

Contact Info

Product

Resources

About